Daily Vitamin D for Sickle-cell Respiratory Complications
Status:
Recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
This study aims to answer the question whether daily oral vitamin D supplementation can
reduce the risk of respiratory or lung complications in children and adolescents with sickle
cell disease. Respiratory problems are the leading causes of sickness and of death in sickle
cell disease. The investigators hypothesize that daily oral vitamin D3, compared to monthly
oral vitamin D, will rapidly increase circulating vitamin D3, and reduce the rate of
respiratory complications by 50% or more within the first year of supplementation in children
and adolescents with sickle cell disease.
This study is funded by the FDA Office of Orphan Products Development (OOPD).
Phase:
Phase 2
Details
Lead Sponsor:
Gary M Brittenham, MD
Collaborator:
FDA Office of Orphan Products Development
Treatments:
Cholecalciferol Ergocalciferols Trientine Vitamin D Vitamins